Patent SG-11201807134R-A (SG)
Title: Transposon system and methods of use
Inventor: SHEDLOCK DEVON
IPC: C12N15/90
Filed: 2017-02-24
Abstract: GFPr% EZI Viability (AAD-ve) FIGURE 1 100 Et 60 u_ 40- P' 4D nucleofector tip) P3 kit Seven, ands Polymer electrodes 4ES 100u1 Saitition T 2400Vi2Omel pulse 5 141 Gold-plated tip Cell nu , Tter Transfe004 . me T VE311 cot Electroporation technology Neon W O 20 17 / 147538 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/147538 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: C12N 15/85 (2006.01) C12N 15/90 (2006.01) (21) International Application Number: PCT/US2017/019531 (22) International Filing Date: 24 February 2017 (24.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/300,387 26 February 2016 (26.02.2016) US (71) Applicant: POSEIDA THERAPEUTICS, INC. [US/US]; 4242 Campus Point Ct #700, San Diego, Califor- nia 92121 (US). (72) Inventors; and (71) Applicants : SHEDLOCK, Devon [US/US]; 4242 Cam- pus Point Ct #700, San Diego, California 92121 (US). HERMANSON, David [US/US]; 4242 Campus Point Ct #700, San Diego, California 92121 (US). (72) Inventor: OSTERTAG, Eric; 4242 Campus Point Ct #700, San Diego, California 92121 (US). (74) Agents: ELRIFI, Ivor R. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, Dis-Published: trict of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: TRANSPOSON SYSTEM AND METHODS OF USE Day 1 post EP (57) : Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon. 111111111111110111011111111111010111110111010111111111110110111110111111111110111111